Vical to scrap genital herpes treatment program after trial fails primary endpoint

Vical to scrap genital herpes treatment program after trial fails primary endpoint

Vical Inc. said Monday a phase 2 trial of its treatment for genital herpes failed to meet its primary endpoint of annualized lesion recurrence rate. In a study of 261 healthy adults with herpes simplex virus type 2, aged 18 to 50, with a self-reported history of 4 to 9 recurrences a year, Vical said the annualized recurrence rate in the placebo group was "far less" than what was expected, meaning there was "significantly less power" to show a vaccine effect in the trial. "We are extremely disappointed with the outcome and based upon these results, we will be terminating the HSV-2 program," said Chief Executive Vijay Samant.

https://finance.yahoo.com/m/d48fa962...html?.tsrc=rss